As of June 2, 2025, Tokai Corp (Gifu) (9729.T) reports a ROE (Return on Equity) of 5.56%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of Tokai Corp (Gifu)'s ROE (Return on Equity)
Over recent years, Tokai Corp (Gifu)'s ROE (Return on Equity) has shown a moderate pattern. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2025-03-31 | 5.56% |
| 2024-03-31 | 6.74% |
| 2023-03-31 | 7.48% |
| 2022-03-31 | 7.54% |
| 2021-03-31 | 7.47% |
This gradual decrease highlights how Tokai Corp (Gifu) manages its efficiency in generating profits from shareholders' equity over time.
Comparing Tokai Corp (Gifu)'s ROE (Return on Equity) to Peers
To better understand Tokai Corp (Gifu)'s position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| Tokai Corp (Gifu) (9729.T) | 5.56% |
| Tibet Rhodiola Pharmaceutical Holding Co (600211.SS) | 26.83% |
| Shanghai Pioneer Holding Ltd (1345.HK) | 13.76% |
| OLBA Healthcare Holdings Inc (2689.T) | 13.19% |
| As One Corp (7476.T) | 12.34% |
| Sinco Pharmaceuticals Holdings Ltd (6833.HK) | 11.50% |
Compared to its competitors, Tokai Corp (Gifu)'s ROE (Return on Equity) is about average compared to peers, reflecting standard industry returns on equity investment.